GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetron Holdings Ltd (NAS:GTH) » Definitions » Float Percentage Of Total Shares Outstanding

Genetron Holdings (Genetron Holdings) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 01, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Genetron Holdings Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Genetron Holdings's float shares is 0.00 Mil. Genetron Holdings's total shares outstanding is 31.62 Mil. Genetron Holdings's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Genetron Holdings's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Genetron Holdings's Institutional Ownership is 0.41%.


Genetron Holdings Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Genetron Holdings's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/31.62
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetron Holdings (Genetron Holdings) Business Description

Industry
Traded in Other Exchanges
N/A
Address
No. 8 Life Science Parkway, 1-2nd Floor, Building 11, Zone 1, Changping District, Beijing, CHN, 102206
Genetron Holdings Ltd is an oncology company in China. It is specialized in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The company's operating segment includes Diagnosis and monitoring - provision for LDT services; Diagnosis and monitoring - sale of IVD products and Development services. It generates maximum revenue from the Diagnosis and monitoring - provision for LDT services segment.